[Form 4] BIO-TECHNE Corp Insider Trading Activity
Bio-Techne Corporation CFO James Hippel reported routine equity compensation activity.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Bio-Techne Corporation CFO James Hippel reported routine equity compensation activity. On April 22, 2026, he exercised stock options to acquire 62,000 shares of common stock at an exercise price of $47.60 per share. In a related F-code tax-withholding disposition, 56,097 shares of common stock were delivered at $58.58 per share to cover obligations. Following these transactions, Hippel directly owned 148,625 Bio-Techne common shares and retained substantial unexercised stock options and restricted stock units with vesting schedules extending through 2028.
Insider Trade Summary
62,000 shares exercised/converted
Exercise
16 txns
Insider
Hippel James
Role
CFO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Options (Right to Buy) | 62,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 62,000 | $0.00 | $0.00 |
| Exercise Price or Tax Liability | Common Stock | 56,097 | $58.58 | $3.29M |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
| holding | Performance Restricted Stock Units | -- | -- | -- |
| holding | Performance Stock Options (Right to Buy) | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
| holding | Performance Restricted Stock Units | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Performance Restricted Stock Units | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
Holdings After Transaction:
Stock Options (Right to Buy) — 493,124 contracts for 369,056 underlying shares (Direct);
Common Stock — 148,625 shares (Direct);
Performance Restricted Stock Units — 67,347 contracts (Direct);
Performance Stock Options (Right to Buy) — 37,314 contracts (Direct);
Restricted Stock Units — 41,809 contracts (Direct)
Footnotes (12)
- F1. Fully exercisable.
- F2. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock.
- F3. Options to purchase 11,305 shares vest on each of 8/15/2023, 8/15/2024, 8/15/2025 and 8/15/2026.
- F4. Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- F5. Options to purchase 11,481 shares vest on each of 8/15/2024, 8/15/2025 and 8/15/2027, and options to purchase 11,480 shares vest on 8/15/2026.
- F6. Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- F7. 4,010 restricted stock units vest on 8/15/2026; and 4,011 restricted stock units vest on 8/15/2027.
- F8. Options to purchase 8,104 shares vest on each of 8/15/2025, 8/15/2026 and 8/15/2027, and options to purchase 8,105 shares vest on 8/15/2028.
- F9. 11,545 restricted stock units vest on 11/1/2026; and 11,544 restricted stock units vest on 11/1/2027.
- F10. Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- F11. 4,903 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 4,904 restricted stock units vest on 8/15/2028.
- F12. Options to purchase 12,544 shares vest on each of 8/15/2026, 8/15/2027 and 8/15/2028.
Key Figures
Options exercised: 62,000 shares
Option exercise price: $47.60/share
Tax-withholding shares: 56,097 shares
+4 more
7 metrics
Options exercised
62,000 shares
Common stock acquired via option exercise on April 22, 2026
Option exercise price
$47.60/share
Exercise price for 62,000 stock options
Tax-withholding shares
56,097 shares
F-code disposition to cover obligations at $58.58/share
Tax-withholding price
$58.58/share
Price for 56,097 common shares delivered for tax/payment
Shares held after
204,722 shares
Direct Bio-Techne common stock ownership after transactions
Options remaining (grant)
124,068 options
Stock options remaining from the 47.60 exercise-price grant
Largest remaining option block
167,328 options
Stock options at $66.97 exercise price expiring August 5, 2027
Key Terms
Restricted Stock Units, Performance Restricted Stock Units, tax-withholding disposition, derivative exercise/conversion, +1 more
5 terms
Restricted Stock Units financial
"security_title: "Restricted Stock Units" with underlying common stock"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Performance Restricted Stock Units financial
"security_title: "Performance Restricted Stock Units" tied to performance goals"
Performance restricted stock units (PRSUs) are promises to deliver company shares to employees or executives only if the business meets specific performance targets and any time-based holding rules. Think of them as a bonus that converts into stock only after set goals are reached, so investors watch PRSUs for two reasons: they can dilute existing shares if paid out, and they signal how closely management’s pay is tied to company performance.
tax-withholding disposition financial
"transaction_action: "tax-withholding disposition" for F-code common stock entry"
A tax-withholding disposition is an event or transaction—such as selling or transferring securities, exercising options, or receiving compensation—that triggers a requirement to hold back part of the payment and remit it to tax authorities. It matters to investors because it reduces the cash they receive immediately and can change the timing and amount of taxable income, like a cashier taking a portion of your sale proceeds to pay taxes before you get the rest.
derivative exercise/conversion financial
"transaction_action: "derivative exercise/conversion" for M-code entries"
Stock Options (Right to Buy) financial
"security_title: "Stock Options (Right to Buy)" with exercise prices and expirations"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Bio-Techne (TECH) CFO James Hippel report in this Form 4?
CFO James Hippel reported routine equity compensation activity. He exercised stock options for 62,000 Bio-Techne common shares and had 56,097 shares withheld in an F-code tax transaction, ending with 204,722 shares held directly after the transactions.
What is the tax-withholding transaction disclosed for BIO-TECHNE Corp (TECH)?
The filing shows an F-code tax-withholding disposition of 56,097 Bio-Techne common shares at $58.58 per share. These shares were delivered to satisfy exercise price or tax liabilities tied to the same equity compensation activity, not an open-market sale by the CFO.
What derivative awards does the Bio-Techne CFO still hold after the Form 4 events?
The filing lists multiple remaining derivative awards, including stock options and restricted stock units on Bio-Techne common stock. Examples include 167,328 options at a $66.97 exercise price expiring in 2027 and 45,220 options at $94.52 expiring in 2029, plus various RSU and performance RSU grants.
Are the Bio-Techne (TECH) Form 4 transactions open-market buys or sales?
No open-market purchases or sales are shown. The key transactions are an M-code option exercise acquiring 62,000 shares and an F-code tax-withholding disposition of 56,097 shares, both tied to equity compensation rather than discretionary market trading by the CFO.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates